The safety and efficacy of the humanized anti–IL-6 mAb clazakizumab was evaluated in a phase II clinical trial in patients with active RA [67] and a phase I/II clinical trial in patients with glucocorticoid-refractory acute graft versus host disease (NCT01530256). Here, IL6 is linked to rheumatoid arthritis.